You sold, you may now leave |
It's because of people like you that the share price is so volatile. You only bought last week and sold already. Again my assertion that you are a gambler and not an investor still stands.Nothing wrong with making money but your giving out on one hand it's a pump and dump and yet here are you buying and selling like a typical pump and dump merchant. |
It's being pumped on X by the usual crowd. |
Interims show cash as at 30th Sept was down to £400k
From their interims announced 6 weeks ago - they had only £400k cash as of Sept 2024.
Financial highlights
· Revenues of £1.2 million (H1 FY2024: £0.5 million)
· Expenditure on R&D maintained at £0.18 million (H1 FY2024: £0.18 million)
· Loss of £0.76 million (H1 FY2024: £1.4 million loss)
· Cash position in the bank at 30 September 2024 was £0.4 million (31 March 2024: £1.2 million) with a further £457k owed by existing debtors |
The Grant news was a month ago. The interims 2 months ago.
There's no company newsflow last week to justify the surge last week.
I maintain my assertion this is a pump/dump.
I sold mine earlier. |
 A best-in-class antibody according to Novartis
Developed by FAB
Sold for $400m+ !
AMSTERDAM, the Netherlands, January 08, 2024 / B3C newswire / -- Calypso Biotech BV (‘Calypso̵7;), a leader in the development of Interleukin15 (IL-15) targeted therapies, announced today that it has entered into an agreement to be acquired by Novartis AG (‘NovartisR17;). Calypso’s shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development milestones of up to $175 million based on the achievement of certain predetermined milestones.
Calypso, a spin-out from Merck, is focused on the research and development of monoclonal antibodies for an array of autoimmune indications, with an expertise in IL-15 biology. IL-15 is a broad, untapped immune axis that controls barrier function and downstream immune cascades in many chronic autoimmune diseases. Calypso’s lead product candidate, CALY-002, is a potential best-in-class therapeutic antibody that binds to and neutralizes Interleukin-15.
The acquisition gives Novartis full rights to CALY-002. Novartis intends to further explore CALY-002 across a wide variety of autoimmune indications with high unmet medical need. CALY-002 is currently evaluated in a Phase 1b trial in patients with Celiac Disease and Eosinophilic Esophagitis.
Alain Vicari, Chief Executive Officer & Co-Founder, Calypso, commented: “We are excited for this transaction with Novartis, a company with relentless commitment to the development of innovative therapies for autoimmune conditions. As part of the Novartis portfolio, CALY-002 is in the best position to be developed effectively, so that it can promptly address unmet medical needs in multiple indications”
Bernard Coulie, Chairman, Calypso, commented: “The transaction with Novartis constitutes the high point in the development path of CALY-002 for the Calypso team. Calypso has established a significantly de-risked profile for CALY-002 as a potential best-in-class therapeutic anti-IL-15 antibody”
Richard Siegel, Head of Immunology Research at Novartis, commented: “Novartis is committed to bringing innovative treatment options forward for patients living with immunological diseases. We’re thrilled to add Calypso’s potential best-in-class antibody to our Immunology pipeline and explore it in a spectrum of autoimmune indications.” |
ShareSoc6 Jan '25 - 09:33 - 9 of 9
You can watch the recent webinar now on YouTube:
FAB's presentation from 27mins in... |
Some nonsense being posted. Read interim results - ceo advised cash breakeven and no need for funding. That was before they secured the 6m grant so there's no chance of any placing anytime soon. Wishful thinking for some |
A placing for what purpose exactly? Please enlighten us with your research that leads you to that conclusion and read the previous RNSs before you start claiming to know more than everyone else |
SikhTT if you judge a share price after 3 hours trading on a Monday morning then I don't believe share trading is for you. You need to judge the performance of a share over a week, month and ideally one year before you decide.To me you just come across as a gambler and not an investor so I'll not be paying much heed to your comments any longer. Best of luck |
Placing soon. |
Agreed pump and dump!! |
Nobody (sicktech etc) said much when it fell from £1 to 4p !!!! And now we only just back at 10p it’s a pump. I think not moron. Management have navigated FAB through the covid storm and the business is fundamentally undervalued. What you are seeing is a genuine re rate. There’s a lot of middle ground between 4p and £1. |
There you go, exactly as predicted.
Hundreds of trades again on no company newsflow.
There aren't hundreds of PI investors.
This is a pump/dump
Look at HVO/Polb, also pumped over the past year. Now threads gone quiet.
sikhthetech5 Jan '25 - 16:00 - 4462 of 4475 Edit
<...>
That's exactly my point. Hundreds of trades, grouped together and price rises substantially. Works both ways. |
Where is this likely to get to this week? 15pTempted to bail out whilst I have a small profit |
Above Ask, now 12p lowest on show.
f |
Lowest Ask on show now sharply lifted to 11.5p, as I type.
f |
That's not just red to blue, that's red to phew! |
Red to blue |
You can watch the recent webinar now on YouTube: |
Decent daily volumes now which is great |
They're still working something in the background, sell limits gone from 25k max, to 325k shares again.... |
Fusion Antibodies (FAB): 7p Target 15pAfter some three years with its shares in the doghouse, made worse by the post pandemic hangover for biotechs, we have seen the FAB phoenix rise from the ashes. The driver in the recent past has been the prospect of what the stock market is very keen on, non-dilutive funding. In this instance, there is the prospect of approximately £1 million of direct funding for research & development initiatives, and access to up to £5 million of capital equipment. All of this coupled by the way that at the interim stage as reported in November FAB revenue had more than doubled, means that fans of the company are looking at a situation where 2025 could be a pivotal year. Before all the good news this autumn as recently as a year ago the shares were trading at 9p, and therefore one would expect this to be easily beaten in Q1 2025. |
From their interims announced 6 weeks ago - they had only £400k cash as of Sept 2024.
Financial highlights
· Revenues of £1.2 million (H1 FY2024: £0.5 million)
· Expenditure on R&D maintained at £0.18 million (H1 FY2024: £0.18 million)
· Loss of £0.76 million (H1 FY2024: £1.4 million loss)
· Cash position in the bank at 30 September 2024 was £0.4 million (31 March 2024: £1.2 million) with a further £457k owed by existing debtors |
Same here just filter this clown |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
